What Is Clioquinol?

Hydroxychloroquine sulfate, a pharmaceutical, the main ingredient is 2--4- (7-chloro-4-quinolinyl) aminopentylethylamino-ethanol sulfate. It is a film-coated tablet and appears white or off-white after removing the coating. For the treatment of discoid lupus erythematosus and systemic lupus erythematosus.

Hydroxychloroquine sulfate

This entry lacks an information bar and an overview map . Supplementing related content makes the entry more complete and can be upgraded quickly. Come on!

Hydroxychloroquine sulfate, a pharmaceutical, the main ingredient is 2--4- (7-chloro-4-quinolinyl) aminopentylethylamino-ethanol sulfate. It is a film-coated tablet and appears white or off-white after removing the coating. For the treatment of discoid lupus erythematosus and

[Drug name] Common name:

The product is 4-

It is reported that hydroxychloroquine sulfate tablets

4-aminoquinoline compounds may undergo the following reactions during long-term treatment, but the adverse reactions and types and incidence of different compounds may be different. (1)

(1) Disable any patients with retinal or visual field changes that can be caused by treatment with 4-aminoquinoline compounds; (2) Disable patients with known allergies to 4-aminoquinoline compounds. (3) Banned for pregnant and lactating women.

(1) The product should be placed out of children's reach. (2) Patients with psoriasis and porphyria can make the original disease worse. Therefore, this product should not be used in these patients, unless the benefit of the patient will exceed its possible risks according to the judgment of the physician. (3) The physician should be fully familiar with the entire contents of this manual before prescribing the product. (4) In some patients receiving long-term or high-dose treatment, irreversible retinal damage has been observed, and retinopathy has been reported to be dose-dependent. (5) The initial (baseline) and regular (once every 3 months) eye examinations (including visual acuity, output slit lamp, fundus mirror, and visual field examination) should be performed when taking this product. (6) If there are any abnormal signs of visual acuity, visual field, or macular area of the retina (such as changes in pigment, loss of foveal reflex) or any visual symptoms (such as flashing and scribing), and cannot be adjusted completely or the cornea is cloudy When explaining, the drug should be stopped immediately and the possible progress should be closely monitored. Even after stopping treatment, retinal changes (and visual impairment) may still progress. (7) All patients treated with this product for long-term treatment should be regularly followed up and checked, including checking the knee and ankle reflexes, and any signs of muscle weakness. If muscle weakness is found, the drug should be discontinued. (8) Patients with liver disease or alcoholism, or combined with drugs known to have liver toxicity, should be used with caution. (9) Patients who have been receiving this product for a long time should be counted regularly. If there is any serious blood disorder that cannot be attributed to the disease being treated, drug withdrawal should be considered. Patients lacking G-6-PD (glucose-6-phosphate dehydrogenase) should be used with caution. (10) Skin reactions can occur when taking this product. Therefore, due attention should be given to any patient who receives the drug with a significant tendency to develop dermatitis. (11) Recommended methods for early diagnosis of "hydroxychloroquine sulfate retinopathy" include checking the macula for subtle pigmentation or loss of foveal reflex with ophthalmoscope, and checking the center with a small red target to see if there is a center in the field of vision Blind spots in the surrounding or central room, or determine the retinal threshold for red. Any unexplained visual symptoms, such as flashes or streaks, should also be suspected as a possible manifestation of retinopathy. (12) When severe poisoning symptoms occur due to overdose or allergies, it is recommended to give ammonium chloride orally (8g daily for adults, divided doses), 3 or 4 days a week, for several months after stopping treatment, because the urine is acidified It can increase renal excretion of 4-aminoquinoline compounds by 20% to 90%. However, caution should be exercised in patients with renal impairment and / or metabolic acidosis.

[Medication for pregnant and lactating women] It is not clear.

[Drug interaction] It is not clear.

[Specifications] 0.1g; 0.2g

[Storage] shading and sealed.